Nabi Biopharmaceuticals has created the Nabi Biologics strategic business unit (SBU) and expanded the role of Dr Raafat Fahim, senior vice president, research, technical and production operations, to include the new position of chief operating officer and general manager of the Biologics SBU.
Nabi Biologics is responsible for advancing the company's protein and immunological products and development pipeline, including Nabi- HB [Hepatitis B Immune Globulin (Human)], Nabi-HB Intravenous [Hepatitis B Immune Globulin (Human) Intravenous], HEBIG [Hepatitis B Immune Globulin (Human) Intravenous], Civacir [Hepatitis C Immune Globulin (Human)], ATG- Fresenius S [Anti-T-Lymphocyte Immune Globulin (Rabbit)], IVIG [Intravenous Immunoglobulin] and Nabi Anti-D [Rho (D) Immune Globulin Intravenous (Human)].
The company also has expanded the role of Jordan Siegel to senior vice president, finance and administration, chief financial officer and Treasurer. In addition to his current role, Siegel will be responsible for the Corporate Shared Services group, which will streamline and improve all Human Resources, Information Technology and Business Development activities at Nabi and support the company's transition into two independent business units - Nabi Biologics and Nabi Pharmaceuticals.
Nabi also provided updates regarding the company's ongoing operations, its strategic alternatives process and the Nabi-HB regulatory efforts, In connection with the formation of the Nabi Biologics and corporate shared services groups the company eliminated 32 jobs - approximately 5 per cent of its workforce - from which it expects to realize nearly $3 million on an annualised basis.
"Since I became Interim chief executive officer and president of Nabi in February of this year, we have focused and energized the approach of our strategic alternatives process and have leveraged the expertise and success of Cato Research to work more effectively with the FDA to secure expanded regulatory approvals for Nabi-HB," said Dr Leslie Hudson, Interim president and chief executive officer of Nabi Biopharmaceuticals. "We are achieving the strategic corporate goals that will help us realize the value of our pipeline - the creation of Nabi Biologics and, soon, Nabi Pharmaceuticals."